Get the Stockscreener App
8.24
3.00%
0.24
After Hours:
8.23
-0.010
-0.12%
Armata Pharmaceuticals Inc stock is traded at $8.24, with a volume of 22,626.
It is up +3.00% in the last 24 hours and up +23.35% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$8.00
Open:
$8.07
24h Volume:
22,626
Relative Volume:
0.38
Market Cap:
$299.99M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-5.0244
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
+1.98%
1M Performance:
+23.35%
6M Performance:
+234.96%
1Y Performance:
+322.56%
1-Day Range:
$7.7991
$8.355
1-Week Range:
$7.4418
$8.40
52-Week Range:
$0.8981
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
8.24 | 291.26M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
MACD Signal: What analysts say about Armata Pharmaceuticals Inc stockJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
Armata Pharmaceuticals FY2025 EPS Boosted by HC Wainwright - MarketBeat
Aug Closing: What is RADCOM Ltds debt to equity ratioMarket Movers & High Accuracy Swing Trade Signals - baoquankhu1.vn
AI Stocks: Can Armata Pharmaceuticals Inc grow without external fundingMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) price target increased by 33.33% to 12.24 - MSN
Phage Therapy Market Set to Witness Significant Growth - openPR.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2%Time to Buy? - MarketBeat
Armata Extends Innoviva Credit, Warrants and Voting Pact - TipRanks
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - MSN
Will Armata Pharmaceuticals Inc. stock gain from lower inflationQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Published on: 2026-01-19 10:14:54 - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24 - Nasdaq
Block Trades: Is Armata Pharmaceuticals Inc stock a smart retirement pickTrade Risk Assessment & Growth Focused Stock Pick Reports - baoquankhu1.vn
Armata Wins FDA Support to Advance Bacteriophage to Phase 3 - TipRanks
Armata Pharmaceuticals Advances AP-SA02 to Phase 3 Study - TradingView — Track All Markets
C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ – Company Announcement - Financial Times
ARMP Stock Quote - richtv.io
Why Armata Pharmaceuticals Inc. (TG1N) stock is upgraded to buyJuly 2025 Weekly Recap & Target Return Focused Picks - ulpravda.ru
What valuation multiples suggest for Armata Pharmaceuticals Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Armata Pharmaceuticals, Inc. Common Stock (NY: ARMP - FinancialContent
Will Armata Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Trend Report & Entry and Exit Point Strategies - Улправда
Will Armata Pharmaceuticals Inc. stock continue dividend increases2025 Price Targets & Community Consensus Trade Alerts - Улправда
Trade Recap: Will Armata Pharmaceuticals Inc. stock deliver long term returnsJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Улправда
Can Armata Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Risk Summary & Scalable Portfolio Growth Methods - ulpravda.ru
Will Armata Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
Will Armata Pharmaceuticals Inc. stock pay special dividendsMarket Sentiment Review & Real-Time Stock Movement Alerts - Улправда
About Us | Oil & Gas JournalArmata Pharmaceuticals, Inc. Common Stock (NYSE:ARMP) Detailed Stock Data - FinancialContent
Will Armata Pharmaceuticals Inc. stock outperform energy sector in 20252026 world cup usa national team round of 16 goalkeepers counter attacking tactical prediction expert opinion - ulpravda.ru
Jones Trading initiates coverage of Armata Pharmaceuticals (ARMP) with buy recommendation - MSN
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Coverage Initiated by Analysts at Jones Trading - Defense World
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? - MSN
Jones Trading Initiates Coverage on Armata Pharmaceuticals (ARMP - GuruFocus
Jones Trading Initiates Coverage on Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - MarketBeat
Jones Trading initiates coverage on Armata Pharmaceuticals stock with Buy rating - Investing.com Canada
Published on: 2026-01-05 08:37:29 - moha.gov.vn
Gap Down: Will Armata Pharmaceuticals Inc stock maintain dividend yieldMarket Growth Report & Risk Controlled Stock Pick Alerts - moha.gov.vn
ARMATA PHARMACEUTICALS INC(NYSEARCA:ARMP) stock News - Chartmill
Day Trade: Is Armata Pharmaceuticals Inc stock among top earnings playsLayoff News & Fast Exit and Entry Strategy Plans - moha.gov.vn
Will Armata Pharmaceuticals Inc stock maintain dividend yieldMarket Risk Summary & Growth Focused Entry Reports - moha.gov.vn
Pharma News: Will Armata Pharmaceuticals Inc stock gain from lower inflation2025 Market WrapUp & Real-Time Buy Signal Alerts - moha.gov.vn
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 2.7% HigherStill a Buy? - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 2.7% Higher – Still a Buy? - Defense World
Aug Closing: Will Armata Pharmaceuticals Inc TG1N stock benefit from sector leadershipJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Is Armata Pharmaceuticals Inc. stock trading near support levelsJuly 2025 Price Swings & Fast Moving Market Watchlists - DonanımHaber
Can Armata Pharmaceuticals Inc. stock deliver surprise earnings beatDip Buying & Safe Capital Growth Tips - Улправда
Can Armata Pharmaceuticals Inc. (TG1N) stock sustain double digit ROEJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Улправда
Why Armata Pharmaceuticals Inc. stock attracts global investorsWeekly Profit Recap & Long-Term Growth Portfolio Plans - Улправда
Armata Pharmaceuticals Earnings Notes - Trefis
Why Armata Pharmaceuticals Inc. stock attracts wealthy investors2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - Улправда
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):